INS and metabolic dysfunction-associated steatotic liver disease: Progression of decrease in tissue insulin sensitivity may lead not only to T2DM but also to dyslipidemia, metabolic syndrome (MetS), or non-alcoholic fatty liver disease (NAFLD).